JP Morgan Chase
RNXT icon

JP Morgan Chase’s RenovoRx RNXT Stock Holding History

JP Morgan Chase’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36
Closed -$36 – 7558
2025
Q1 		$36 Sell
36
-4
-10% -$5 ﹤0.01% 7034
2024
Q4 		$52 Buy
+40
New +$46 ﹤0.01% 7125
2023
Q4 		– Sell
-9
Closed -$11 – 7824
2023
Q3 		$11 Buy
+9
New +$16 ﹤0.01% 7281

Other funds holding RNXT

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NPT
Nixon Peabody Trust Boston, Massachusetts $1.26B AUM 24.14% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

JP Morgan Chase's RNXT Position: Q2 2025 in Review

JP Morgan Chase sold out of RenovoRx (RNXT) in Q2 2025, closing a stake of 36 shares — an estimated $36 sold.

JP Morgan Chase first reported a position in RNXT in Q3 2023 and held it in 3 quarters. The position peaked at $52 in Q4 2024. 25 funds tracked by Wall St. Rank hold RNXT as of Q2 2025.

  • JP Morgan Chase reported no remaining RenovoRx position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 36 RenovoRx shares in Q2 2025, an estimated $36.
  • JP Morgan Chase first reported a position in RenovoRx in Q3 2023 and held it in 3 quarters.
  • JP Morgan Chase's RenovoRx position peaked at $52 in Q4 2024.
  • 25 funds tracked by Wall St. Rank held RenovoRx as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.